{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for haloperidol root_references_citation in Reference Text / Citation (approximate match)
Status:
Possibly Marketed Outside US
Source:
REVERSE IT KIT
Source URL:
First approved in 1968
Source:
NDA204017
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
LAURYL LACTATE is an inactive component of 5 DAY (aluminum zirconium tetrachlorohydrex glycine liquid) used to reduce underarm perspiration.
Status:
Possibly Marketed Outside US
Source:
NCT02307396: Phase 4 Interventional Completed Schizophrenia
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Zuclopenthixol is indicated the management of the manifestations of schizophrenia and other mental illnesses with disturbances in thinking, emotional reactions and behaviour. It is also used to treat the manic phase of manic depressive illness. Zuclopenthixol, a thioxanthene derivative, has high affinity for both dopamine D1 receptors and
dopamine D2 receptors. Zuclopenthixol also has high affinity for α1-adrenergic and 5-HT2
receptors. Zuclopenthixol (CLOPIXOL®) is avavilable in the form of tablets and solution for intramuscular injections.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (UNKNOWN)
Aluminum lactate is effective for treatment of dentinal hypersensitivity that was confirmed in the experiments of daily home use of a dental rinse, containing this substance. Aluminum lactate also was studied on rodents. Experiments have revealed, that subchronic exposure of this substance could lead to the memory reduce. This effect can be achieved by reducing the protein expression of low-density lipoprotein receptor protein-1, influencing the transportation of amyloid-beta peptides (Aβ), and leading to the accumulation of Aβ.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M032
(2017)
Source URL:
First approved in 2017
Source:
BEST FACE FORWARD by ASPIRE BRANDS INC
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M006
(2015)
Source URL:
First approved in 2006
Source:
M006
Source URL:
Class:
MIXTURE
